Pfizer Upgrading Terre Haute Plant In Response To FDA Warning Letter
Executive Summary
Pfizer will complete an upgrade to its Terre Haute, Ind. manufacturing facility within six months, the company said after receiving a 1warning letter from FDA Jan. 30
You may also be interested in...
Risk-Based GMPs: FDA Priorities Will Reflect Exposure, Compliance Record
FDA's risk-based inspection model will consider a product's breadth of use when assigning inspection priorities
Pfizer Near Resolution Of GMP Warning Letter; Lilly, Merck Provide Updates
Pfizer expects a re-inspection of its Terre Haute, Ind. injectable manufacturing facility before the end of the month, the company told investors during an April 17 conference call
GMP Compliance Guidances Should Be Increased, Lilly’s Miner Says
FDA needs to issue more guidances on GMP compliance topics, Lilly Corporate GMP Compliance Leader David Miner, PhD, said